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Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in the industrialized world. Familial aggregation of
cardiovascular risk factors is a frequent finding, but genetic factors affecting its presentation are still poorly understood. The
calpain 10 gene (CAPN10) has been associated with type 2 diabetes (T2DM), a complex metabolic disorder with increased
risk of cardiovascular disease. Moreover, the CAPN10 gene has been associated with the presence of metabolic syndrome
(MS) in T2DM and in polycystic ovary syndrome (PCOS). In this work, we have analysed whether the polymorphisms
UCSNP44, -43, -19 and -63 are related to several cardiovascular risk factors in the context of MS. Molecular analysis of
CAPN10 gene was performed in 899 individuals randomly chosen from a cross-sectional population-based epidemiological
survey. We have found that CAPN10 gene in our population is mainly associated with two indicators of the presence of
insulin resistance: glucose levels two hours after a 75-g oral glucose tolerance test (OGTT) and HOMA values, although
cholesterol levels and blood pressure values are also influenced by CAPN10 variants. In addition, the 1221/1121
haplogenotype is under-represented in individuals that fulfil the International Diabetes Federation (IDF) diagnostic criteria
for MS. Our results suggest that CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population.
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Introduction
The CAPN10 gene is located at 2q37 and encodes a ubiquitously
expressed member of the calpain cysteine protease family.
Horikawa et al. [1] positionally cloned CAPN10 as type 2 diabetes
mellitus (T2DM) gene in Mexican American and Finnish
populations. In that study, the common G allele of UCSNP43
polymorphism and the haplotype combination 112/121 (that
comprises UCSNP43, -19 and -63 polymorphisms) were associ-
ated with an increased risk of T2DM. Since then, the role of
CAPN10 has been examined in different ethnic groups with uneven
results [2]. Genetic heterogeneity between populations is thought
to be responsible for the different polymorphisms and haplotype
combinations at CAPN10 locus that have been found associated
with an increased risk of T2DM. In fact, a report by Fullerton et al.
[3] has shown an unusual degree of geographic structure at this
locus, especially at UCSNP19 and UCSNP63 sites, suggesting
positive natural selection acting either on CAPN10 gene or on
closely linked locus. Despite these differences, two meta-analyses
have confirmed the association of the UCSNP43 G allele with a
higher risk of T2DM, whereas showed that the effect of the 112/
121 haplogenotype was over-estimated in the initial studies [4,5]
Genetic studies have associated UCSNP43, UCSNP19 and the
haplotype combination reported by Horikawa et al. [1] with insulin
levels [6–9]. Some of these genetic associations are accompanied
by physiological studies that support the CAPN10 role in
proinsulin processing, insulin secretion and insulin action [10–
14]. In this way, other insulin related disorders have been linked to
CAPN10 gene such as polycystic ovary syndrome (PCOS). PCOS is
a common endocrine disorder of women of reproductive age,
characterized by chronic anovulation, infertility and hyperandro-
genemia. This syndrome, in which insulin resistance is considered
a key feature, has been independently associated with CAPN10
allelic variants by Erhman et al. [15] and our group [16,17] and
has been recently confirmed in a meta-analysis [18].
Metabolic syndrome (MS) is characterized by abdominal
obesity, atherogenic dyslipidemia, raised blood pressure, insulin
resistance/glucose intolerance, prothrombotic and proinflamma-
tory state [19]. Currently insulin resistance is considered the
underlying mechanism for these metabolic alterations [20,21].
The CAPN10 gene has been associated with several components
of MS such as hypertension in Chinese [22,23] and African-
American [24], elevated body mass index (BMI) in Japanese
[25], cholesterol levels in Chinese [26] and hipertrigliceridemia
in obese Swedish individuals [27]. Recently, the 111/121
haplotype combination has been associated with an increased
risk of metabolic syndrome in Korean T2DM patients [28].
However, an analysis of this gene in individuals that fulfil the
diagnostic criteria of MS in general population has not been
performed.
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2953The aim of this study was to analyse the role of CAPN10 allelic
variants in genetic susceptibility to MS and related metabolic traits
in a Spanish population-based survey. Our main outcome is the
identification of association between CAPN10 gene variants and
two estimators of insulin resistance: the glucose levels after an oral
glucose tolerance test (OGTT) and the HOMA index. In addition,
we have observed association with blood pressure and cholesterol
levels and with MS under the IDF definition. Altogether, our
results contribute to the notion of CAPN10 as an insulin resistance
gene.
Materials and Methods
Patients
This population based study includes 899 non related
Caucasian men (n=427, 47.5%) and women (n=472, 52.5%)
who were recruited by a simple random sampling approach from a
cross-sectional population-based epidemiological survey in the
province of Segovia in Central Spain (Castille), aimed at
investigating the prevalence of anthropometric and physiological
parameters related to obesity and other components of MS [29].
The age of this population ranged between 35 and 76 years (mean
age 54.03611.69 years). Subjects with previous diagnosis of type 1
diabetes were excluded from the study. All subjects gave their
written consent to participate in the study. The study protocol was
approved by the Ethics Committee of the Hospital Clı ´nico San
Carlos of Madrid.
Phenotype measurements
Anthropometric measurements included body mass index (BMI,
kg/m
2) and waist circumference (WC, cm). Systolic (SBP) and
diastolic blood pressures (DBP) were measured three times in the
seated position after 10 minutes of rest to the nearest even digit by
use of a random-zero sphygmomanometer.
After an overnight fast period, 20 ml of blood were obtained
from an antecubital vein without compression. Plasma glucose was
determined in duplicate by a glucose-oxidase method adapted to
an Autoanalyzer (Hitachi 704, Boehringer Mannheim, Germany).
Total cholesterol, triglycerides (TG) and high-density lipoprotein
cholesterol (HDL-c) were determined by enzymatic methods using
commercial kits (Boehringer Mannheim, Germany). Low-density
lipoprotein cholesterol (LDL-c) was calculated by the Friedewald
formula. Serum insulin concentration was determined by RIA
(Human Insulin Specific RIA kit, Linco Research Inc., St Louis
MO, USA).
An oral glucose tolerance test (OGTT) using 75 g of glucose was
performed according to the WHO recommendations and the
results were interpreted in accordance with Genuth et al. [30].
Insulin resistance was estimated by the homeostasis model
assessment (HOMA-IR) method according to the formula: Insulin
(mU/ml)6Glucose (mmol/l)/22.5 [31,32].
The metabolic syndrome status was established according to
ATPIII definition (SM_ATPIII) [32]: presence of at least three
components between abdominal obesity (WC$102 cm men,
88 cm women), hipertrigliceridemia ($150 mg/dl), hypertension
($85/130 mmHg), HDL-c (,40 mg/dl men, ,50 mg/dl wom-
en) and fasting glucose$100 mg/dl. We have also classified
subjects according to the recently International Diabetes Feder-
ation (IDF) worldwide definition of the metabolic syndrome for
Europid populations (SM_IDF) [33]. In this last definition, central
adiposity (defined as WC$94 cm for men and $80 cm for
women) is a prerequisite risk factor for the diagnosis of the
syndrome; two of the following factors are also necessary: raised
TG level (.150 mg/dl) or specific treatment for this abnormality;
reduced HDL-c (,40 mg/dl males, ,50 mg/dl females) or
specific treatment; raised blood pressure (SBP$130 mmHg or
DBP$85 mmHg) or treatment of previously diagnosed hyperten-
sion, raised fasting plasma glucose (FPG$100 mg/dl) or previ-
ously diagnosed T2DM.
Table 1 summarize the basal characteristics of the study
population, expressed as phenotypic means6standard deviations
for the quantitative traits and crude prevalences for the dichotomic
traits.
DNA extraction
DNA extraction from 300 ml of frozen peripheral blood was
performed in a MagNapure LC Instrument (Roche Diagnostics),
using MagNa Pure LC DNA Isolation kit (Roche Diagnostics)
according to the manufacturer’s instructions. Aliquots of DNA at
5 ng/ul were obtained to carry out PCR reactions.
Genotyping
We have determined allele status at the single nucleotide
polymorphisms previously associated with metabolic syndrome
traits UCSNPs-44,-43,-19 and -63 according the nomenclature
and definitions reported by Horikawa et al. [1] and Evans et al.
[34].
UCSNP44 and –43. These two SNPs were amplified in a
same amplicon of 204 bp using previously described primers 43F/
43R [16]. The reverse primer was biotin labeled for genotypes
determination in a PSQ
TM 96 (Pyrosequencing AB, Uppsala,
Sweden). The internal sequencing primer was 59 CAG GGC GCT
CAC GCT TGC 39. This instrument allows the simultaneous
analysis of 96 samples using pyrosequencing techniques [35].
Table 1. Baseline characteristics of study subjects.
CONTINUOUS TRAITS Men (n=427) Women (n=472)
Mean SD Mean SD
Age (years) 53.49 11.73 54.51 11.64
BMI (kg/m
2) 27.56 3.33 27.63 4.70
Waist circumference (cm) 95.36 8.96 85.56 11.20
SBP (mmHg) 126.65 16.58 124.75 19.46
DBP(mmHg) 78.79 9.12 77.78 9.99
Fasting glucose (mmol/L) 5.26 1.68 4.89 1.28
2h-glucose (mmol/L) 5.97 2.31 6.19 2.23
Fasting insulin (pmol/L) 78.24 48.54 79.68 59.46
HOMA 3.07 2.10 3.07 2.97
TGs (mmol/L) 1.31 0.82 1.00 0.54
Cholesterol (mmol/L) 5.61 1.04 5.52 1.05
HDL-c (mmol/L) 1.39 0.41 1.63 0.47
LDL-c (mmol/L) 3.62 0.94 3.44 0.93
DICHOTOMIC TRAITS N% N %
Smoking 142 33.3 73 15.5
Physical activity 237 55.5 312 66.2
Alcohol consumption 347 81.3 184 39
T2DM 37 8.7 36 7.9
SM_ATPIII 69 17 108 23.9
SM_IDF 90 21.8 121 26.8
doi:10.1371/journal.pone.0002953.t001
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previously described forward primer (19F) [16] and new
designed reverse primer (19R2: 59-GCA GGG TCT AAG CAG
CAG CTA C-39). Amplicon sizes were 152 bp for allele 1 (2
repeats of 32 bp sequence) and 184 bp for allele 2 (3 repeats of 32
bp sequence) and were differentiated in 2% agarose gel.
UCSNP63. Allele status was determined using previously
described procedure [16].
Statistical Analysis
To analyze differences in genotype distribution, chi-square
association studies for MS and T2DM and test for deviation of
Hardy-Weinberg equilibrium (HWE), we have used tests adapted
from Sasieni [36] at the online resource available at the Institute
for Human Genetics, Munich, Germany (http://ihg.gsf.de).
For genotype quantitative analysis, we have performed an
analysis of variance using the GLM procedure included in SPSS
software (Ver. 11.0.0., LEAD Technologies, Inc). Normality of the
dependent variables was assessed by Kolmogorov-Smirnov test
and, when necessary, we applied mathematical transformations
(natural logarithm or square root) prior to the analysis. The
adjusted percentage of the phenotypic variance explained by each
genotype was estimated by subtracting the adjusted R
2 value for a
model that includes the genotype from the R
2 for a model that
excludes it. The Levenes test of equality of error variances was also
performed for each analysis. In addition, all values from
individuals under antihypertensive, antidiabetic or hypocholester-
olemic medication were eliminated of the QTL analysis.
Haplotype analysis was performed using the THESIAS software
(http://www.genecanvas.org) based on the SEM algorithm [37].
This method allows to estimate haplotype frequencies and
haplotype effects by comparison to a reference (the intercept)
taken here as the most frequent one. Haplotypes effects are
expressed as mean effects (increases/decreases of the phenotypic
mean with respect to the intercept’s one).
All the studies were adjusted for sex, age, BMI, smoking (defined
as present or past history of smoking of at least five cigarettes per
day for a minimum of 5 years), alcohol consumption (defined as a
daily intake of more than 10 g), and physical activity. Interaction
effects of age, sex and BMI were explored.
Results
Genotypic association analysis
Allele 1 frequencies at the four polymorphic loci within CAPN10
gene (UCSNP44, -43, -19 and -63) in our population were 0.85 at
UCSNP44 (allele T), 0.74 at UCSNP43 (allele G), 0.36 at
UCSNP19 (2 repeats of 32 bp) and 0.95 at UCSNP63 (allele C)
(Table 2). These allelic frequencies do not differ from previously
determined by our group in healthy controls from Granada,
Southern Spain (p.0.06) [16]. All genotypic frequencies fit those
expected by the HWE (p.0.06), except for the UCSNP63
polymorphism, for which we detected a high degree of
homozygosity (p=0.002); genotypes of five out the eight
individuals homozygous for the polymorphic allele at this locus
were confirmed by direct sequencing.
The genotype distributions at UCSNP44 and UCSNP19 loci
were shown to influence glucose levels after an OGTT (x
2
2 d.f.,
p=0.008 and p=0.011 respectively), explaining each of them
around a 3% of the phenotypic variance observed for this trait
(Table 3). Individuals homozygous for the less frequent alleles C at
UCSNP44 and 2-repeats allele at UCSNP19 loci were associated
with a significant lower glucose levels when compared with the
remaining genotypes; conversely, homozygotes for the more
frequent alleles (T at UCSNP44 and 3-repeats allele at
UCSNP19), have higher OGTT values. Both UCSNP44 and
UCSNP19 polymorphisms are also associated with the HOMA
index, an indirect measure of insulin resistance; this trait is also
influenced by the UCSNP43 locus. The effect size observed in
terms of HOMA variance explained by CAPN10 polymorphisms is
higher than the observed for the 2-hours glucose levels, being all of
them over a 4.6%.
The UCSNP19 polymorphism was also associated with two
other MS related phenotypes: blood pressure (BP) and LDL-c
levels, although the contribution to the phenotype is more modest
that the observed for OGTT and HOMA (1.1$r
2#2.4).
Heterozygotes for this variant have lower BP values despite
increased LDL-cholesterol levels whereas the homozygous pres-
ence of allele 2 is associated with lower LDL-c levels.
We have also observed that homozygotes for the UCSNP63
wild type allele have lower total and LDL cholesterol levels
(p#0.027) but given the departure of the HWE observed at this
locus, these results must be interpreted with caution.
We have not found any association with BMI, waist
circumference, triglycerides or HDL-c values (data not shown).
We have neither observed association with T2DM nor with
MS_ATPIII, but the heterozygous presence of the UCSNP19
polymorphism was associated with a higher risk for MS_IDF
(OR=1.89 [1.04–3.44], p=0.036). Interaction analyses of
CAPN10 variants with age, sex and BMI were not significant,
suggesting that the effects of these polymorphisms do not differ
substantially between subjects for these reasons.
Haplotypic association analysis
The haplotype reconstruction showed five possible haplotypes
(1121, 1221, 2111, 1111 and 1112 for UCSNP44, UCSNP43,
UCSNP19 and UCSNP63) according to previous reports from
other populations (Table 4). Haplotypic frequencies are 0.37 for
1121, 0.25 for 1221, 0.15 for 2111, 0.16 for 1111 and 0.06 for
1112. For performing the association analysis, CAPN10 haplotypes
were compared with a reference haplotype, taken here as the most
frequent one (haplotype 1121). In this analysis, we only observed a
significant contribution of the 2111 haplotype to the OGTT
(p=0.002), having the carriers of this haplotype 9.8% lower 2-
hours glucose levels in accordance to the genotypic association
analysis, since allele 2 at UCSNP44 locus only appears in this
background.
Haplogenotypic association analysis
Finally, we have assigned haplotype pairs to all study subjects
and performed haplogenotypic association analysis. In our
Table 2. Genotype distribution at CAPN10 UCSNP44, -43, -19
and -63 sites and analysis of Hardy-Weinberg equilibrium
(HWE).
SNP F ALlELE 1 GENOTYPIC DISTRIBUTION P HWE
11 12 22
UCSNP44 T.C 0.85 637 (71.9%) 226 (25.5%) 23 (2.6%) 0.604
UCSNP43 G.A 0.74 495 (56.6%) 311 (35.6%) 68 (7.8%) 0.062
UCSNP19 del/ins 0.36 120 (13.7%) 396 (45.3%) 359 (41.0%) 0.511
UCSNP63 C.T 0.95 795 (90.3%) 77 (8.8%) 8 (0.9%) 0.002
Allele nomenclature according to Horikawa et al. [1] and Evans et al. [34]
doi:10.1371/journal.pone.0002953.t002
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frequency from 0.93% to 17.11% (Table 5). In order to estimate
the global haplogenotypic effect in the association analysis, only
the haplotype pairs with a population frequency over 0.05 were
computed. The only trait for which this global test was significant
was LDL-c levels (x
2
7 d.f., p=0.027), with two associated
protective haplogenotypes (1221/1121 and 2111/1111), whereas
a trend was observed for total cholesterol (x
2
7 d.f., p=0.054) and
SBP (x
2
7 d.f., p=0.063). Given that LDL-c is the main fraction of
total cholesterol, a high concordance is observed in the association
analysis since 1221/1121 and 2111/1111 are also total cholesterol
lowering haplogenotypes, although the effect size is lower.
For SBP only the 2111/1221 haplogenotype individual analysis
was significant (p=0.024), showing a 3.8% decrease with respect
to the remaining haplogenotypes. The 2111/1121 haplogenotype
was associated with a reduction in both insulin and HOMA values
Table 3. Genotypic association analysis.
PHENOTYPE SNP GENOTYPE MEAN SE adjusted R2 P VALUE
2h-GLUCOSE (mmol/L) UCSNP44 2 DF 3.3 0.008
11 5.89 ,0.01 3.1 0.012
12 5.58 ,0.01 - Ns
22 4.75 0.01 3.0 0.016
UCSNP19 2 DF 3.1 0.011
11 5.39 ,0.01 2.8 0.014
12 5.75 ,0.01 - Ns
22 6.01 ,0.01 2.8 0.014
HOMA index UCSNP44 2 DF 4.9 0.052
11 2.77 0.03 5 0.017
12 2.42 0.04 5 0.017
22 2.58 0.12 - Ns
UCSNP43 2 DF 4.6 0.055
11 2.62 0.03 - Ns
12 2.64 0.04 - Ns
22 3.22 0.07 4.7 0.016
UCSNP19 2 DF 4.7 0.048
11 2.41 0.05 - Ns
12 2.59 0.03 - Ns
22 2.84 0.03 4.7 0.022
SBP (mmHg) UCSNP19 2 DF 2.4 0.021
11 124.14 1.49 - Ns
12 120.44 0.86 2.5 0.007
22 123.01 0.86 - Ns
DBP (mmHg) UCSNP19 2 DF 1.1 0.015
11 78.30 0.89 - Ns
12 75.98 0.51 1.1 0.005
22 77.56 0.51 - Ns
CHOLESTEROL (mmol/L)L UCSNP63 2 DF 0.5 0.098
11 5.51 0.05 0.6 0.016
12 5.80 0.13 0.5 0.025
22 5.71 0.43 - Ns
LDL-cholesterol (mmol/L) UCSNP19 2 DF 1.9 0.060
11 3.47 0.01 - Ns
12 3.62 0.06 2.1 0.018
22 3.44 0.06 - Ns
UCSNP63 2 DF 1.4 0.079
11 3.51 0.04 1.5 0.027
12 3.78 0.12 1.5 0.024
22 3.58 0.38 - Ns
Only the association studies which obtained a p value under 0.05 are shown. SE: standard error; Ns: Not significant. All values are adjusted by age, sex, alcohol
consumption, smoking, physical activity and BMI.
doi:10.1371/journal.pone.0002953.t003
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homozygous presence of the 2111 is associated with a significant
decrease (18.4%) of the glucose levels after an OGTT (p=0.016).
Finally, the homozygous presence of the UCSNP19 polymor-
phism in the 1221/1121 haplogenotype is associated with a lower
risk of suffering from MS_IDF (OR=0.51 [0.26–0.99], p=0.044).
No association was observed with either MS_IDF or T2DM.
Discussion
Complex disorders represent the majority of human diseases,
but their genetic bases are still unclear. CAPN10 gene has been
associated with type 2 diabetes in some studies, but other analyses
failed to reproduce this finding. It may be due to differences in
effect size in different ethnic backgrounds, disease allele frequen-
cies, marker allele frequencies and extent of linkage disequilibrium
at CAPN10 locus between populations that also accounts for the
diverse CAPN10 alleles associated with insulin resistance pheno-
types in those studies. However, distinct meta-analyses and also
functional studies have confirmed the role of CAPN10 in insulin
resistance phenotypes [4,5,12,13,38,39].
We have observed increased levels of both 2-hours glucose and
HOMA values associated with the UCSNP44 TT genotype.
Conversely, homozygous presence of the allele C (allele 2) is
associated with higher glucose tolerance. This allele seems to be
the most determining one in our population, since the unique
haplotype in which the allele 2 exists was the only associated in the
haplotypic analysis. Moreover, all but one of the haplogenotypes
associated to the different phenotypes analysed comprise this
allele. In all cases, the allele C confers protection from
cardiovascular risk, not only regarding OGTT, HOMA or even
insulin levels, but also regarding BP and plasma cholesterol.
However, given the low frequency of this allele, we can not draw
final conclusions. Previous studies have described an association of
the allele C at UCSNP44 locus with T2DM [14,34,38]. This
divergence could be related to specific population genetic
background or to random chance in our results due to low
population frequency. Functional studies suggest that UCSNP44 is
located in an enhancer element and might affect CAPN10
expression [1]. Also this polymorphism is in perfect linkage
disequilibrium (r
2=1) with a missense mutation Thr504Ala (SNP-
110) and two polymorphisms in the 59-UTR region (UCSNP134
and UCSNP135) [38].
The other outstanding polymorphism in our population is
UCSNP19, which is also associated with the OGTT and HOMA
values, increased in the homozygotes for the 3-repeats allele (allele
2), and with LDL-c levels, that are in contrast decreased in these
individuals. This antagonistic action is also observed in the
heterozygous state, resulting in lower BP values despite increased
LDL-c levels. The UCSNP19 polymorphism has been previously
associated with other insulin resistance syndrome, PCOS, and with
cholesterol levels in these women [16–18].
We have not found evidence of association either of the
UCSNP43 G allele or the 112/121 haplogenotype originally
described by Horikawa et al [1] as T2DM susceptibility variants,
with any of the metabolic related traits analysed in this work. By
contrast, the UCSNP43 A allele (allele 2) which is in complete LD
with UCSNP19 allele 2, seems to be related to higher HOMA
values in our population, but only in the homozygous state. The
unique haplotype in which the UCSNP43 allele 2 is present
(haplotype 1221), when combined with the 1121 haplotype, is
associated with a lower risk of MS_IDF suggesting that the effect
of the UCSNP43 only exists in the homozygous state or that the
association of the 1221/1121 with MS_IDF is due to the
heterozygous presence of the UCSNP19 allele 2. However, the
haplogenotypic analysis is the least powerful one due to reduced
sample size in each analysed group, so we can not rule out the
possibility of type 1 error, especially given that we have not applied
correction for multiple testing.
We have observed increased total and LDL cholesterol values
associated with heterozygosity at UCSNP63 locus, but given the
high deviation from HWE observed in our population, we must
interpret this result with caution. Interestingly, the T2DM and MS
subpopulations are in HWE (p=1.000 and p=0.115, respectively)
(Table 6). We have examined HWE at UCSNP63 locus in the
report by Kang et al. [28]. We found that deviation from HWE
(HWD) exists in this T2DM population, with an excess of allele 2
homozygotes (p=0.0004) and an inbreeding coefficient F of 0.18.
Conversely, in a recent analysis of CAPN10 performed on 312
healthy Korean subjects, HWD is not observed (p=0.543) [40]. In
Caucasians, a CAPN10 gene analysis in the Botnia region of
Finland, shows that HWE is also altered in the control population
(Finland) (p=0.045) but is preserved in the T2DM population
(p=0.416) [9]. In a report by Lynn et al. [8], there is no evidence
of HWD in a non diabetic British population (p=0.170), but an
independent analysis according to T2DM familial antecedents,
shows that it is only true in those individuals with T2DM relatives,
showing the individuals without T2DM familial antecedents again
an excess of UCSNP63 allele 2 (p=0.037). These data could
reflect the existence of selective pressures and high geographic
structure affecting CAPN10 locus identified by several reports in
accordance with the thrifty genotype hypothesis [3,41,42]. This
hypothesis posits that T2DM genes have been submitted to the
effects of natural selection [43].
In summary, our results support a role for CAPN10 in MS and
related metabolic traits. However, the physiological mechanisms
underlying the genetic associations described in this and other
reports are not entirely clear. The pleiotropic effects of CAPN10
could be related with the key role of insulin in the harmonization
of glucidic and lipidic metabolisms. The identification of other loci
Table 4. Haplotypic frequencies and association analysis with OGTT values in Spanish population
HAPLOTYPE F N MEAN (95%CI) PHENOTYPIC EFFECT (95%CI). P VALUE
1121 0,37 270 3,10 (2,94 23,27) 1 (Reference) -
1221 0,25 183 3,14 (2,95 23,33) 20,04 (20,23–0,30) 0.762
2111 0,15 110 2,80 (2,53 23,07) 20,30 (20,63– 20,02) 0.002
1111 0,16 117 2,95 (2,68 23,22) 20,15 (20,50–0,19) 0.289
1112 0,06 43 2,70 (2,24 23,17) 20,40 (20,91–0,11) 0.145
F: population frequency.
doi:10.1371/journal.pone.0002953.t004
CAPN10 and Insulin Resistance
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PLoS ONE | www.plosone.org 6 August 2008 | Volume 3 | Issue 8 | e2953interacting CAPN10 could provide clues about the physiological
pathways involved. In this way, genetic interaction between
CAPN10 and CYP19 gene has been suggested to increases
susceptibility to T2DM [44]. CYP19 aromatase encodes an
enzyme involved in the steroid hormones synthesis from
cholesterol, a biological process in which insulin is known to take
part [45]. Aromatase knockout mice (ArKO) show increased intra-
abdominal fat distribution and reduction of glucose oxidation,
suggesting an important role for this metabolic route in the
maintenance of lipid homeostasis in both males and females [46].
Members of the calpain family are involved in several biological
processes through the proteolitic regulation of numerous tran-
scription factors, but the physiological substrates for CAPN10 are
still unknown. Further analysis considering gene-gene interactions
will help resolve these questions.
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